Newsflash

LIFT Cancer Trial Starting in China
A new clinical trial based on Dr. Zheng Cui's granulocyte technology is starting at Beijing's 304 Hospital. Go to The LIFT Cancer Treatment Trial Site for more information.
Breast Cancer
Powerful New Radiation For Breast Cancer Treatment in Colum Print

By Ashley Ball 

News 3 On Your Side

April 02 2008 

 

The American Cancer Society estimates that over 180,000 women will be diagnosed with breast cancer this year.

 

This new treatment supplements regular radiation treatments for breast cancer and is completely non evasive.

 

The machine resembles a mammography machine but it uses little to no pressure. The treatment is called Accu Boost and this is the first machine in the south eastern United States. Digital imaging allows doctors to pinpoint the exact area they need to target- decreasing the area subjected to radiation and delivering a stronger dose.

 

Marriann Turner is the first patient in the south east to recieve the treatment. She says the sucess and ease of the treatment helps her forget she has cancer, "With this you might be a little bit tired but I have learned to pace myself and it really teaching myself about me and how easy this can be."

 

Dr. Mark Taylor is a surgeon at the Columbus Clinic. He says, “This is just another example of our top notch medical treatment that is available here in Columbus and people don't necessarily need to go to the big city to receive excellent care.”

 

Accu Boost also allows doctors to deliver radiation to the site from multiple directions. Conventional radiation only allows for one. Before this non evasive procedure, large needles were used to help direct the radiation.

 

Doctors hope that in the future Accu Boost could shorten radiation treatment times. 

 
Even After Surgery, Women Remain Unsure of Breast Cancer Survival Rates Print
Newswise — Women diagnosed with early-stage breast cancer who choose breast-conserving surgery and radiation therapy live as long as those who opt for breast removal, research shows. According to a new study, however, only half of women clearly understand survival rates associated with these procedures, and minority women are even less likely to have adequate information.

Even after going through the treatment process, many women do not understand the risks and benefits, said lead author Sarah Hawley, Ph.D.

The study looked at 1,132 women from Detroit and Los Angeles who had undergone surgical treatment for ductal carcinoma in situ (DCIS) or invasive but not metastatic breast cancer. The women reported their race and ethnicity, knowledge of survival and recurrence, and cancer topics they discussed with their surgeons, who the study also surveyed.

The results appear in the latest online issue of the journal Health Services Research.

Only 51 percent of women knew that a mastectomy and a lumpectomy plus radiation had the same five-year survival rate. Forty-eight percent of women reported not knowing whether cancer recurrence rates were the same for mastectomy as they were for a lumpectomy with radiation.

“Overall, women were not generally well informed about the risks and benefits of the treatment that they received,” said Hawley, a research assistant professor in the University of Michigan Health System and research investigator at the Ann Arbor VA Healthcare System.

The survey also revealed that African-American and Hispanic women were less likely to know about breast cancer survival and recurrence, as were older women and those with less education.

Women who said that their surgeons discussed both treatment options did know more about survival and recurrence rates, but minority women still lagged in survival and recurrence knowledge, Hawley said.

Treatment location did not improve knowledge of cancer survival and recurrence.

“The authors’ finding of racial and ethnic differences in knowledge of survival and recurrence according to surgical treatment are concerning because of their implications about possible suboptimal communication between surgeons and their ethnic minority patients,” said Leah Karliner, M.D., an assistant professor of medicine at the University of California San Francisco who was not affiliated with the study.

However, Karliner said that the findings are only associations and that readers cannot draw cause-and-effect conclusions about the results. “Women’s knowledge after they have already received their surgical treatment may not accurately reflect their knowledge at the time they decided on that treatment,” she said.

For those undergoing treatment, “I would advise women that is not only okay to ask questions, but that doctors expect it. They should always ask all of their questions before deciding on a treatment option and make sure they understand the reasons behind their doctors’ recommendations for or against a particular treatment,” Karliner said.

The study received funding from the National Cancer Institute, part of the National Institutes of Health.

 

 

Health Services Research is the official journal of the AcademyHealth and is published by Blackwell Publishing on behalf of the Health Research and Educational Trust. For information, contact Jennifer Shaw, HSR Business Manager at (312) 422-2646 or  This e-mail address is being protected from spambots. You need JavaScript enabled to view it . HSR is available online at http://www.blackwell-synergy.com/loi/hesr.

Hawley ST, et al. Racial/ethnic disparities in knowledge about risks and benefits of breast cancer treatment: Does it matter where you go? Health Services Research online, 2008.

 
RCR welcomes START, showing that fewer fractions of radiotherapy work for breast cancer treatment Print

Published: 03/18

LONDON, UK - (HealthTech Wire) - The Royal College of Radiologists welcomes the latest results from the Standardisation of Breast Radiotherapy Trial (START), which has found that radiotherapy treatment for breast cancer can now be given in fewer treatments than the international standard of 25 fractions. Local recurrence in the breast has reduced markedly over the last 10 years and now only affects one woman in 25. This is due to improved cancer care and quality assurance. In addition radiotherapy side effects are now less marked.

Professor Andy Adam, President of the Royal College of Radiologists said, “START represents the culmination of twenty years of study conducted by researchers from the UK, and as such is an important milestone in radiotherapy research. It shows that treatment for women with breast cancer can be given in a quicker and more convenient way, and it has the potential to improve the treatment of breast cancer patients across the world.”

Dr Michael Williams, Vice-President of the Royal College of Radiologists said, “This study confirms that a shorter treatment is both effective and safe. Three quarters of women in the UK are already treated with short treatments, but this was a decision driven mainly by lack of resources. Further investment in radiotherapy services is required to ensure prompt and appropriate treatment. This has been recognised in the development of the English Cancer Reform Strategy, and we look forward to working to carry out its recommendations.”

 
<< Start < Prev 1 2 3 4 Next > End >>

Page 1 of 4